CURE

Calendar of CURE/Yale BioHaven seminars for Fall 2010 now available. more

9/14
8:45 am - 6:00 pm
Ubifrance, the French Agency for international business development, cordially invites CURE members to this year's second French Biotech Tour, which aims to connect French and American Biotech companies specialized in neuroscience, inflammation, and auto-immune diseases. Philadelphia, PA. more

9/16
6:00 pm - 7:30 pm
CURE/Yale BioHaven presents Al Mann: 'Creating a successful medical device enterprise.' Hope Auditorium, Yale University, 315 Cedar Street, New Haven. more

10/5
Deadline for nominations for the Lemelson-MIT prize, awarded to an outstanding mid-career inventor who has developed a patented product or process of significant value to society. more

10/14
4:00 pm - 7:00 pm
Hartford Hospital Research Symposium. 'Personalized Medicine and Genomics: The Future is Now.' RSVP by 10/1 to 860.545.5620. Heublein Hall, Education & Resource Center, Hartford Hospital, Hudson Street, Hartford. more

10/27
4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Cobalt Therapeutics. Anlyan Center, Yale University, 300 Cedar Street, New Haven. more

11/18
4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Biodel Inc. Anlyan Center, Yale University, 300 Cedar Street, New Haven. more

12/7
5:30 pm - 7:30 pm
CURE Holiday Party. Café George, 300 George Street, New Haven. Watch for details.

Amarin Pharma Inc.
Third Floor - Mystic Packer Building
12 Roosevelt Avenue
Mystic, CT 06355

Phone: 860 572 4979
Fax: 860 572 4940
Website: http://www.amarincorp.com

General Information
Amarin is a clinical-stage biopharmaceutical company with the lead program entering Phase 3 for hypertriglyceridemia. Amarin’s cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease.

Research Activities
AMR101, a prescription grade Omega-3 fatty acid, is an ultra pure (~97%) ethyl ester of eicosapentaenoic acid. Phase 3 development of AMR101 in hypertriglyceridemia is planned to commence in 2009. Hypertriglyceridemia is a condition associated with increased levels of heart disease diagnosed in over 10 million people in the US.